INSTITUTIONAL PRE-DOCTORAL NRSA

癌症是一系列疾病，其控制将最终需要对允许细胞以不受控制的方式开始分裂并随后侵入正常组织的事件的基本理解。细菌和真菌机会性感染已成为免疫功能低下患者发病率和死亡率的主要原因，特别是那些接受高剂量化疗治疗实体瘤或长期治疗白血病、淋巴瘤和其他癌症相关血液疾病的患者。拟议的培训计划的目标将是指导博士生在基础研究的多学科方面的致癌作用和发病机制。主要目标是培养年轻科学家，他们将继续从事癌症生物学和宿主-病原体相互作用的职业，并随后对他们感兴趣的特定研究领域产生影响。参与该计划的教师代表了医学院最具竞争力的科学家，他们对致癌作用和发病机理感兴趣，来自病理学，生物化学和分子生物学，生理学和分子医学，医学，微生物学和免疫学等部门。参与者包括M博士。你（肺癌的分子遗传学），J.C. Willey（致癌物与肺癌有关）、R. Ruch（细胞-细胞通讯），J. P. Trempe（癌症的基因治疗），M. Ratnam（癌症的新化疗方法），L. Faber（孕激素、免疫抑制剂与乳腺癌）、M.佩雷拉（预防结肠直肠癌），D. L. Sawicki（病毒复制的调节）、M.波义耳（纤溶酶原激活和细菌发病机制。G.T.科尔（免疫调节与机会性真菌侵袭有关）和D. W. Metzgar（细胞因子调节免疫）。所有的博士前学生将通过现有的俄亥俄州医学院的医学科学计划录取，无论是疾病的分子基础或分子和细胞生物学领域的方案浓度。除了程序集中的要求，学生在这个培训计划，称为癌症的分子发病机制（MPC）将被要求采取2个癌症为导向的课程，并参加培训计划活动（研讨会系列，杂志俱乐部，研究会议和研究务虚会）。

Cancer is a spectrum of diseases whose control will ultimately require a basic understanding of the events that permit cells to begin to divide in an uncontrolled manner and subsequently invade normal tissue. Bacterial and fungal opportunistic infections have emerged as major causes of morbidity and mortality in immunocompromised patients, particularly those undergoing high dose chemotherapy for the treatment of solid tumors, or prolonged treatment for leukemia, lymphoma and other cancer-related hematologic disorders. The objectives of the proposed training program will be to direct predoctoral students in basic research on multi-disciplinary aspects of carcinogenesis and pathogenesis. The major goal is to train young scientists who will continue their careers in cancer biology and host-pathogen interactions, and subsequently make an impact on their specific area of research interest. The faculty participants in this program represent the medical school's most competitive scientists with interest in carcinogenesis and pathogenesis, and are drawn from the Departments of Pathology, Biochemistry and Molecular Biology, Physiology and Molecular Medicine, Medicine, and Microbiology and Immunology. The faculty participants include Drs. M. You (molecular genetics of lung cancer), J.C. Willey (carcinogens implicated in lung cancer), R. Ruch (cell-cell communication), J.P. Trempe (gene therapy of cancer), M. Ratnam (novel chemotherapeutic approaches to cancer), L. Faber (progestins, immunosuppressants and breast cancer), M. Pereira (prevention of colorectal carcinoma), D.L. Sawicki (regulation of viral replication), M. Boyle (plasminogen activation and bacterial pathogenesis. G.T. Cole (immunomodulation related to opportunistic fungal invasion), and D.W. Metzgar (cytokine regulation of immunity). All predoctoral students will matriculate through the existing Medical College of Ohio's Medical Sciences Program in either the Molecular Basis of Disease or Molecular and Cellular Biology areas of programmatic concentration. In addition to the requirements of the programmatic concentration, students in this training program, called Molecular Pathogenesis of Cancer (MPC) will be required to take 2 cancer-oriented courses and participate in training program activities (seminar series, journal club, research conferences and research retreats).